Susceptibilities of Gram-negative bacilli from hospital- and community-acquired intra-abdominal and urinary tract infections: a 2016–2017 update of the Chinese SMART study

References

• Biedenbach D, Bouchillon S, Hackel M, et al. Dissemination of NDM metallo-β-lactamase genes among clinical isolates of Enterobacteriaceae collected during the SMART global surveillance study from 2008 to 2012. Antimicrob Agents Chemother. 2015;59:826–830.25403666
   PubMed Web of Science ®Google Scholar
• Paterson DL, Rossi F, Baquero F, et al. In vitro susceptibilities of aerobic and facultative Gram-negative bacilli isolated from patients with intra-abdominal infections worldwide: the 2003 Study for Monitoring Antimicrobial Resistance Trends (SMART). J Antimicrob Chemother. 2005;55:965–973. doi:10.1093/jac/dki11715849262
   PubMed Web of Science ®Google Scholar
• Lu PL, Liu YC, Toh HS, et al. Epidemiology and antimicrobial susceptibility profiles of Gram-negative bacteria causing urinary tract infections in the Asia-Pacific region: 2009–2010 results from the Study for Monitoring Antimicrobial Resistance Trends (SMART). Int J Antimicrob Agents. 2012;40(Suppl):S37–43. doi:10.1016/S0924-8579(12)70008-022749057
   PubMed Web of Science ®Google Scholar
• Jean SS, Coombs G, Ling T, et al. Epidemiology and antimicrobial susceptibility profiles of pathogens causing urinary tract infections in the Asia-Pacific region: results from the Study for Monitoring Antimicrobial Resistance Trends (SMART), 2010–2013. Int J Antimicrob Agents. 2016;47:328–334. doi:10.1016/j.ijantimicag.2016.01.00827005459
   PubMed Web of Science ®Google Scholar
• Institute CaLS. Performance Standards for Antimicrobial Susceptibility Testing. 26thed. Wayne, PA: Clinical and Laboratory Standards Institute; 2016 CLSI supplement M100S.
   Google Scholar
• Solomkin JS, Mazuski JE, Bradley JS, et al. Diagnosis and management of complicated intra-abdominal infection in adults and children: guidelines by the surgical infection society and the infectious diseases society of America. Clin Infect Dis. 2010;50:133–164. doi:10.1086/64955420034345
   PubMed Web of Science ®Google Scholar
• Morrissey I, Hackel M, Badal R, et al. A review of ten years of the Study for Monitoring Antimicrobial Resistance Trends (SMART) from 2002 to 2011. Pharmaceuticals (Basel). 2013;6:1335–1346. doi:10.3390/ph611133524287460
   PubMedGoogle Scholar
• Yang Q, Zhang H, Wang Y, et al. A 10 year surveillance for antimicrobial susceptibility of Escherichia coli and Klebsiella pneumoniae in community- and hospital-associated intra-abdominal infections in China. J Med Microbiol. 2013;62:1343–1349. doi:10.1099/jmm.0.059816-023741022
   PubMed Web of Science ®Google Scholar
• Demonchy E, Courjon J, Ughetto E, et al. Cefoxitin-based antibiotic therapy for extended-spectrum beta-lactamase-producing Enterobacteriaceae prostatitis: a prospective pilot study. Int J Antimicrob Agents. 2018;51:836–841. doi:10.1016/j.ijantimicag.2018.01.00829378342
   PubMed Web of Science ®Google Scholar
• Cardarella S, Ogino A, Nishino M, et al. Clinical, pathologic, and biologic features associated with BRAF mutations in non-small cell lung cancer. Clin Cancer Res. 2013;19:4532–4540. doi:10.1158/1078-0432.CCR-13-065723833300
   PubMed Web of Science ®Google Scholar
• Villar HE, Danel F, Livermore DM. Permeability to carbapenems of Proteus mirabilis mutants selected for resistance to imipenem or other beta-lactams. J Antimicrob Chemother. 1997;40:365–370.9338488
   PubMed Web of Science ®Google Scholar
• Neuwirth C, Siebor E, Duez JM, et al. Imipenem resistance in clinical isolates of Proteus mirabilis associated with alterations in penicillin-binding proteins. J Antimicrob Chemother. 1995;36:335–342.8522463
   PubMed Web of Science ®Google Scholar
• Li J, Zou MX, Wang HC, et al. An outbreak of infections caused by a Klebsiella pneumoniae ST11 clone coproducing Klebsiella pneumoniae carbapenemase-2 and RmtB in a Chinese teaching hospital. Chin Med J (Engl). 2016;129:2033–2039. doi:10.4103/0366-6999.18904927569227
   PubMed Web of Science ®Google Scholar
• Zheng B, Dai Y, Liu Y, et al. Molecular epidemiology and risk factors of carbapenem-resistant Klebsiella pneumoniae infections in Eastern China. Front Microbiol. 2017;8:1061. doi:10.3389/fmicb.2017.0106128659886
   PubMed Web of Science ®Google Scholar
• McCann E, Srinivasan A, DeRyke CA, et al. Carbapenem-nonsusceptible Gram-negative pathogens in ICU and Non-ICU settings in US hospitals in 2017: a multicenter study. Open Forum Infect Dis. 2018;5:ofy241. doi:10.1093/ofid/ofy24130364442
   PubMed Web of Science ®Google Scholar
• Routsi C, Pratikaki M, Platsouka E, et al. Risk factors for carbapenem-resistant Gram-negative bacteremia in intensive care unit patients. Intensive Care Med. 2013;39:1253–1261. doi:10.1007/s00134-013-2914-z23604133
   PubMed Web of Science ®Google Scholar
• Livorsi DJ, Chorazy ML, Schweizer ML, et al. A systematic review of the epidemiology of carbapenem-resistant Enterobacteriaceae in the United States. Antimicrob Resist Infect Control. 2018;7:55. doi:10.1186/s13756-018-0346-929719718
   PubMed Web of Science ®Google Scholar
• Perez F, Van Duin D. Carbapenem-resistant Enterobacteriaceae: A menace to our most vulnerable patients. Cleve Clin J Med. 2013;80:225–233. doi:10.3949/ccjm.80a.1218223547093
   PubMed Web of Science ®Google Scholar
• O’Fallon E, Kandel R, Schreiber R, et al. Acquisition of multidrug-resistant gram-negative bacteria: incidence and risk factors within a long-term care population. Infect Control Hosp Epidemiol. 2010;31:1148–1153. doi:10.1086/65659020923286
   PubMed Web of Science ®Google Scholar
• Zhang H, Kong H, Yu Y, et al. Carbapenem susceptibilities of Gram-negative pathogens in intra-abdominal and urinary tract infections: updated report of SMART 2015 in China. BMC Infect Dis. 2018;18:493. doi:10.1186/s12879-018-3109-630268102
   PubMed Web of Science ®Google Scholar